Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis

References

• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. New Engl J Med 2005;353: 172–87.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248 , a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–37.
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329–38.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584–90.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med 2011;364:501–13.
   PubMed Web of Science ®Google Scholar
• Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 2009;48: 9–17.
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 2008;9: 117–23.
   PubMed Web of Science ®Google Scholar
• Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: A meta-analysis. Clin Genitourin Cancer 2009;7:11–9.
   PubMed Web of Science ®Google Scholar
• Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta- analysis. Acta Oncol 2008;47:176–86.
   PubMed Web of Science ®Google Scholar
• Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta- analysis of clinical trials. Lancet Oncol 2009;10:967–74.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280–5.
   PubMed Web of Science ®Google Scholar
• Schutz FA, Je Y, Choueiri TK. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials. Crit Rev Oncol Hematol 2011;80:291–300.
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Su X, Shah R, Wu S. Risk of cytopenia with sunitinib in patients with renal cell cancer and non-RCC cancers: A meta-analysis. In: Proceedings of the 2010 Genitourinary Cancers Symposium, ASCO, abstract 393. San Francisco, California: ASCO.
   Google Scholar
• Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2- negative advanced breast cancer. Breast Cancer Res Treat 2010;121:121–31.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011;11:82–92.
   PubMed Web of Science ®Google Scholar
• Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized phase III study. J Clin Oncol 2012;30:921–9.
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dhakil S, Patel T, Sundaram S, Fabian C, Kozloff M, et al. SABRE-B: An evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010;21:2370–6.
   PubMed Web of Science ®Google Scholar
• Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660–4.
   PubMed Web of Science ®Google Scholar
• Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92: 3531–4.
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, et al. The clinical implications of sunitinib- induced hypothyroidism: A prospective evaluation. Br J Cancer 2008;99:448–54.
   PubMed Web of Science ®Google Scholar
• Sabatier R, Gravis G, Deville J, Salem N, Brunelle S, Walz J, et al. Hypothyroidism and survival during sunitinib therapy in metastatic renal cell cancer: A prospective observational analysis. In: Proceedings of the 2009 Genitourinary Cancers Symposium, ASCO, abstract 317. Orlando, Florida: ASCO.
   Google Scholar
• Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99:81–3.
   PubMed Web of Science ®Google Scholar
• Pfizer: Sutent prescribing information. Available from: http://www.pfizer.com/files/products/uspi_sutent.pdf
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute: Common Toxicity Criteria version 3. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012;118:1252–9.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30:1371–7.
   PubMed Web of Science ®Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743–8.
   PubMed Web of Science ®Google Scholar
• Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: Clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009;9:82.
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959–68.
   PubMed Web of Science ®Google Scholar
• George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154–60.
   PubMed Web of Science ®Google Scholar
• Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 2009;10:757–63.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010;65:649–60.
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010;116:163–7.
   PubMed Web of Science ®Google Scholar
• Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21–8.
   PubMed Web of Science ®Google Scholar
• Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010;15:285–92.
   PubMed Web of Science ®Google Scholar
• Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, et al. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymph 2010;51:2222–9.
   PubMed Web of Science ®Google Scholar
• Ping G, Hui-Min W, Wei-Min W, Bao-Hui H. Sunitinib in pretreated advanced non-small-cell lung carcinoma: A primary result from Asian population. Med Oncol 2011;28: 578–83.
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study. Ann Oncol 2011;22:335–40.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Kuruvilla J, Chua N, Lee C, Macdonald DA, Al-Tourah AJ, et al. Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: A clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leuk Lymph 2011;52:833–41.
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 2011;6:1117–20.
   PubMed Web of Science ®Google Scholar
• Novello S, Camps C, Grossi F, Mazieres J, Abrey L, Vernejoux JM, et al. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol 2011;6:1260–6.
   PubMed Web of Science ®Google Scholar
• Gervais R, Hainsworth JD, Blais N, Besse B, Laskin J, Hamm JT, et al. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 2011;74:474–80.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119–29.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:974–5; author reply 6–7.
   PubMedGoogle Scholar
• Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol 2008;69:669–72.
   PubMed Web of Science ®Google Scholar
• Salem AK, Fenton MS, Marion KM, Hershman JM. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 2008;18:631–5.
   PubMed Web of Science ®Google Scholar
• Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351–5.
   PubMed Web of Science ®Google Scholar
• Braun D, Kim TD, le Coutre P, Kohrle J, Hershman JM, Schweizer U. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 2012;97:E100–5.
   PubMed Web of Science ®Google Scholar
• Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560–76.
   PubMed Web of Science ®Google Scholar
• Makita N, Miyakawa M, Fujita T, Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010;20:323–6.
   PubMed Web of Science ®Google Scholar
• Hershman JM, Liwanpo L. How does sunitinib cause hypothyroidism?Thyroid 2010;20:243–4.
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, Dumez H, Fieuws S, Wildiers H, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell carcinoma. J Clin Oncol 2008;26:280s (Abstract 5126).
   Google Scholar
• Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma: Blessing or curse?Cancer 2011;117:534–44.
   PubMed Web of Science ®Google Scholar
• Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 2011;29: 807–13.
   PubMed Web of Science ®Google Scholar
• Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nature Clin Pract Oncol 2007;4:674–52.
   PubMedGoogle Scholar
• Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?Ann Oncol 2012;23:714–21.
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst 2012;104:93–113.
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nature Rev Clin Oncol 2009;6:219–28.
   PubMed Web of Science ®Google Scholar
• Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P. Tyrosine kinase inhibitors and modifications of thyroid function tests: A review. Eur J Endocrinol 2009; 160:331–6.
   PubMed Web of Science ®Google Scholar
• Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA 2004;291:228–38.
   PubMed Web of Science ®Google Scholar
• Wolter P, Dumez H, Schoffski P. Sunitinib and hypothyroidism. New Engl J Med 2007;356:1580; author reply 1581.
   PubMed Web of Science ®Google Scholar